Synthesis of analogues of Congo red and evaluation of their anti-prion activity

Journal of Medicinal Chemistry

Volumn 47, Issue 22, 2004, Pages 5515-5534

  Sellarajah, Shane ^a   Lekishvili, Tamuna ^b   Bowring, Claire ^b   Thompsett, Andrew R ^b   Rudyk, Helene ^a   Birkett, Christopher R ^c   Brown, David R ^b   Gilbert, Ian H ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b University of Bath   (United Kingdom)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIS METHYL 4 [[[4' (AMINOCARBONYL) 1,1' BIPHENYL 4 YL]CARBONYL]AMINO] 3 HYDROXYBENZOATE; CONGO RED DERIVATIVE; PRION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; DRUG SYNTHESIS; MOUSE; NEUROTOXICITY; NONHUMAN; PRION; PROTEIN POLYMERIZATION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANIMALS; BENZAMIDES; BIOPOLYMERS; BRAIN; CELL LINE; CONGO RED; HYDROXYBENZOIC ACIDS; INHIBITORY CONCENTRATION 50; MICE; PRIONS; PRPC PROTEINS; PRPSC PROTEINS; SCRAPIE; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS;

EID: 6044272950     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049922t     Document Type: Article

References (38)

1. Bounias, M.; Purdey, M. Transmissible spongiform encephalopathies: a family of etiologically complex diseases - a review. Sci. Total Environ. 2002, 297, 1-19.
2. Dormont, D. Prion diseases: pathogenesis and public health concerns. FEBS Lett. 2002, 529, 17-21.
3. Hill, A. F.; Desbruslais, M.; Joiner, S. The same prion strain causes vCJD and BSE. Nature 1997, 389, 448-450.
4. Prusiner, S. B. Prions. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13363-13383.
5. Supattapone, S.; Nishina, K.; Rees, J. R. Pharmacological approaches to prion research. Biochem. Pharmacol. 2002, 63, 1383-1388.
6. Muller, W. E. G.; Laplanche, J. L.; Ushijima, H.; Schroder, H. C. Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease. Mech. Aging Dev. 2000, 116, 193-218.
7. Gilbert, I. H.; Rudyk, H. Inhibitors of protease resistant prion formation. Int. Antiviral News 1999, 7, 78-82.
8. Koster, T.; Singh, K.; Zimmermann, M.; Gruys, E. Emerging therapeutic agents for transmissible spongiform encephalopathies: a review. J. Vet. Pharmacol. Ther. 2003, 26, 315-326.
9. Farquhar, C.; Dickinson, A.; Bruce, M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 1999, 353, 117-117.
10. Korth, C.; May, B. C. H.; Cohen, F. E.; Prusiner, S. B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9836-9841.
11. May, B. C. H.; Fafarman, A. T.; Hong, S. B.; Rogers, M.; Deady, L. W. et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 3416-3421.
12. Kocisko, D. A.; Baron, G. S.; Rubenstein, R.; Chen, J.; Kuizon, S. et al. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J. Virol. 2003, 77, 10288-10294.
13. Kirby, L.; Birkett, C. R.; Rudyk, H.; Gilbert, I. H.; Hope, J. In vitro cell-free conversion of bacterial recombinant PrP to Prp-(res) as a model for conversion. J. Gen. Virol. 2003, 84, 1013-1020.
14. Rudyk, H.; Vasiljevic, S.; Hennion, R. M.; Birkett, C. R.; Hope, J. et al. Screening Congo red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J. Gen. Virol. 2000, 81, 1155-1164.
15. Rudyk, H.; Knaggs, M. H.; Vasiljevic, S.; Hope, J.; Birkett, C. et al. Synthesis and evaluation of analogues of congo red as potential compounds against transmissible spongiform. encephalopathies. Eur. J. Med. Chem. 2003, 38, 567-579.
16. Ingrosso, L.; Ladogana, A.; Pocchiari, M. Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol. 1995, 69, 506-508.
17. Demaimay, R.; Harper, J.; Gordon, H.; Weaver, D.; Chesebro, B. et al. Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J. Neurochem. 1998, 71, 2534-2541.
18. Klunk, W. E.; Debnath, M. L.; Koros, A. M. C.; Pettegrew, J. W. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci. 1998, 63, 1807-1814.
19. Klunk, W. E.; Debnath, M. L.; Pettegrew, J. W. Development of small-molecule probes for the beta-amyloid protein of alzheimers-disease. Neurobiol. Aging 1994, 15, 691-698.
20. Gray, L. E.; Ostby, J. S. The effects of prenatal administration of azo dyes on testicular development in the mouse-a structure activity profile of dyes derived from benzidine, dimethylbenzidine, or dimethoxybenzidine. Fundam. Appl. Toxicol. 1993, 20, 177-183.
21. Bos, R. P.; Koopman, J. P.; Theuws, J. L. G.; Henderson, P. T. The essential role of the intestinal flora in the toxification of orally-administered benzidine-based dyes-internal exposure of rats to benzidine after intestinal azo reduction. Mutat. Res. 1987, 181, 327-327.
22. Talaska, G. Aromatic amines and human urinary bladder cancer: Exposure sources and epidemiology. J. Environ. Sci. Health, Part C 2003, 21, 29-43.
23. Demaimay, R.; Chesebro, B.; Caughey, B. Inhibition of formation of protease-resistant prion protein by Trypan blue, Sirius red and other Congo red analogues. Arch. Virol. 2000, 277-283.
24. Clarke, M. C.; Haig, D. A. Evidence for the multiplication of scrapie agent in cell culture. Nature 1970, 225, 100-101.
25. Birkett, C. R.; Hennion, R. M.; Bembridge, D. A.; Clarke, M. C.; Chree, A. et al. Scrapie strains maintain biological phenotypes on propagation in a cell line in culture. EMBO J. 2001, 20, 3351-3358.
26. Ziao, N.; Graton, J.; Laurence, C.; Le Questel, J.-Y. Amino and cyano N atoms in competitive situations: which is the best hydrogen bond acceptor? A crystallographic database investigation. Acta Crystallogr., Sect. B 2001, 57, 850-858.
27. Link, C. D.; Johnson, C. J.; Fonte, V.; Paupard, M. C.; Hall, D. H. et al. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol. Aging 2001, 22, 217-226.
28. Styren, S. C.; Hamilton, R. L.; Styren, G. C.; Klunk, W. K. X-34, a fluorescent derivative of Congo red: A novel histochemical stain for Alzheimer's disease pathology. J. Histochem. Cytochem. 2000, 48, 1223-1232.
29. Brown, D. R.; Hafiz, F.; Glasssmith, L. L.; Wong, B. S.; Jones, I. M. et al. Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J. 2000, 19, 1180-1186.
30. Demaimay, R.; Adjou, K. T.; Beringue, V.; Demart, S.; Lasmezas, C. I. et al. Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J. Virol. 1997, 71, 9685-9689.
31. Masullo, C.; Macchi, G.; Xi, Y. G.; Pocchiari, M. Failure to Ameliorate Creutzfeldt-Jakob Disease with Amphotericin-B Therapy. J. Infect. Dis. 1992, 165, 784-785.
32. Barret, A.; Tagliavini, F.; Forloni, G.; Bate, C.; Salmona, M. et al. Evaluation of quinacrine treatment for prion diseases. J. Virol. 2003, 77, 8462-8469.
33. Tagliavini, F.; McArthur, R. A.; Canciani, B.; Giaccone, G.; Porro, M. et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997, 276, 1119-1122.
34. Priola, S. A.; Raines, A.; Caughey, W. S. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000, 287, 1503-1506.
35. Aguzzi, A.; Haass, C. Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 2003, 302, 814-818.
36. Brown, D. R. PrPSc-like prion protein peptide inhibits the function of cellular prion protein. Biochem. J. 2000, 352, 511-518.
37. Wong, B. S.; Wang, H.; Brown, D. R.; Jones, I. M. Selective oxidation of methionine residues in prion proteins. Biochem. Biophys. Res. Commun. 1999, 259, 352-355.
38. Brown, D. R. Prion protein peptide neurotoxicity can be mediated by astrocytes. J. Neurochem. 1999, 73, 1105-1113.